Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial

MLA

Xinxin Zhang, et al. “Arsenic Trioxide and All-Trans Retinoic Acid (ATRA) Treatment for Acute Promyelocytic Leukemia in All Risk Groups: Study Protocol for a Randomized Controlled Trial.” Trials, vol. 19, no. 1, Sept. 2018, pp. 1–7. EBSCOhost, https://doi.org/10.1186/s13063-018-2812-3.

APA

Xinxin Zhang, Huiyun Zhang, Limei Chen, Mengchang Wang, Jieying Xi, Xin Liu, Ming Xie, Dengzhe Li, Ekamjyot Singh Gulati, Sha Gong, & Huaiyu Wang. (2018). Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial. Trials, 19(1), 1–7. https://doi.org/10.1186/s13063-018-2812-3

Chicago

Xinxin Zhang, Huiyun Zhang, Limei Chen, Mengchang Wang, Jieying Xi, Xin Liu, Ming Xie, et al. 2018. “Arsenic Trioxide and All-Trans Retinoic Acid (ATRA) Treatment for Acute Promyelocytic Leukemia in All Risk Groups: Study Protocol for a Randomized Controlled Trial.” Trials 19 (1): 1–7. doi:10.1186/s13063-018-2812-3.